Mavyret Exclusivity and Patent Landscape
Mavyret (glecaprevir/pibrentasvir) is an antiviral medication used to treat chronic hepatitis C virus (HCV) infection [1]. Understanding its patent and exclusivity status is crucial for anticipating market changes and the potential introduction of generic alternatives.
When is Mavyret expected to lose exclusivity?
The exact date of Mavyret's loss of exclusivity is complex due to multiple patents covering the drug [2]. However, based on patent expiry projections, key patents for Mavyret are anticipated to expire in the coming years. For instance, some formulations and methods of use patents could expire around 2027-2030 [2]. DrugPatentWatch.com tracks these expirations and provides detailed information on patent landscapes for pharmaceuticals like Mavyret [2].
What patents protect Mavyret?
AbbVie holds a portfolio of patents covering Mavyret. These patents encompass various aspects of the drug, including the active pharmaceutical ingredients (glecaprevir and pibrentasvir), specific formulations, and methods of treating HCV infection [2]. The interplay and expiration dates of these various patents influence the overall exclusivity period.
How does Mavyret's patent expiry affect generic competition?
As Mavyret's patents expire, it opens the door for generic manufacturers to seek approval for their own versions of the drug [2]. The introduction of generics typically leads to lower drug prices and increased market competition. The timing of generic entry will depend on the expiration of all relevant patents and the successful navigation of the regulatory approval process by generic companies.
What is the mechanism of action for Mavyret?
Mavyret is a combination therapy targeting multiple stages of the HCV life cycle. Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor. By inhibiting these viral proteins, Mavyret prevents the virus from replicating and spreading within the body [1].
What are the clinical outcomes for Mavyret?
Clinical trials have demonstrated high sustained virologic response (SVR) rates for Mavyret across various HCV genotypes and patient populations [1]. SVR is generally considered a cure for hepatitis C. The drug has shown efficacy in both treatment-naïve and treatment-experienced patients, including those with cirrhosis [1].
Sources:
1. https://www.fda.gov/drugs/drug-approvals/mavyret-glecaprevir-pibrentasvir
2. https://drugpatentwatch.com/